Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis Save
A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).
A phase 2b, randomised, multicentre trial used a double-blind, randomized, placebo-controlled, multiple-dose study design. They enrolled 2990 active PsA adult patients and randomized them to receive placebo, 30 mg, 15 mg, or 5 mg zasocitinib once daily for 12 weeks, with a 4-week safety follow-up. The primary endpoint was the ACR)20 response at week 12.
The week 12 ACR20 responses significantly favorted Zasocitinib:
- 30mg 54.2%;
- 15 mg 53.3%
- Placebo 29.2% (P = .002)
ACR50 responses were similarly significant (30 mg-26.4%; 15 mg-26.7%; placebo-9.7%). 30 mg zasocitinib had a higher number of ACR70 responses (13.9% versus 5.6%). Other superior secondary outcomes included the PASI 75 responses (45.7% versus 15.4%), and MDA (29.2% versus 12.5%).
No new safety signals or clear dose-dependent laboratory parameter changes were identified.
Zasocitinib 30 mg and 15 mg appears to be safet and effectiving in PsA, with no new safety concerns.
More ACR Coverage:
ADD THE FIRST COMMENT
Disclosures
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.